

News Release

Lonza Group Ltd
Muenchensteinerstrasse 38
CH-4002 Basel, Switzerland
www.lonza.com

Lonza Closes Acquisition Of Cambrex Bio-Businesses

Basel, 06 February 2007 - Lonza, the global life sciences company, announced today that it has completed the acquisition of the Research Bioproducts business and the Microbial Biopharmaceutical business of the US company Cambrex, published in October 2006. The closing of the deal follows the consent of Cambrex shareholders on 5 February 2007.

The Microbial Biopharmaceuticals business will be integrated into the existing Lonza Biopharmaceuticals business sector and supports Lonza's microbial biopharmaceutical growth. The Research Bioproducts will be positioned as a stand-alone business unit and renamed as Lonza Bioscience. Its leading position in cell-based research, endotoxin detection and cell therapy manufacturing is highly complementary to Lonza's Biopharmaceuticals business.

"The closing of the Cambrex Bio-Businesses acquisitions marks an important milestone within Lonza's transformation into a focused life sciences company," said Stefan Borgas, Chief Executive Officer of Lonza. "Together we will build upon Lonza's track record to deliver outstanding products and services to support our customer's research and manufacturing processes, and extend our reach further with the addition of the new Bioproducts business. By joining forces globally, we strengthen Lonza's strategic position and our growth potential as a worldwide leader servicing our life sciences customers."

Commencing today, Lonza will start integrating the two Cambrex units and its approximately 1000 employees into the existing structure of the company.

About Lonza

Founded in 1897, Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers' needs from research to final product manufacture. Lonza is the global leader in the production and support of pharmaceutical active ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2006 Lonza had sales of CHF 2.91 billion. Further information can be found at www.lonza.com.

For further information:

Investor Relations /Media inquiries:

Lonza Ltd
Margot Connor
Tel +41 61 316 8566
Fax +41 61 316 9566
Mobile +41 79 401 2832
margot.connor@lonza.com

Lonza America Inc.
Melanie Disa
Tel +1 201 316 9413
Fax +1 201 696 3533
Mobile + 1 845 270 0548
melanie.disa@lonza.com

Media inquiries German:

Lonza Ltd
Dominik Werner
Tel +46 61 316 8798
Fax +41 61 316 9798
Mobile +41 79 470 6308
dominik.werner@lonza.com